An example, for the treatment of patients with multiple myeloma, uses the anti PD-1 mAb PDR001 in combination with the mAb CJM112 (targeting IL-17) or with the Smac Mimetic LCL161 drug (an IAP inhibitor) (NCT03111992). Here, PDCD1 is linked to plasma cell myeloma.